Literature DB >> 12752320

Pretransplant MELD score as a predictor of outcome after liver transplantation for chronic hepatitis C.

Nicholas N Onaca1, Marlon F Levy, George J Netto, Mark J Thomas, Edmund Q Sanchez, Srinath Chinnakotla, Carlos G Fasola, Jeffrey S Weinstein, Natalie Murray, Robert M Goldstein, Goran B Klintmalm.   

Abstract

The Model of End-Stage Liver Disease (MELD) score, an accurate predictor of mortality in patients awaiting liver transplantation (OLTX), did not predict graft or patient survival in the post-transplant setting. Our aim was to test the model in patients who underwent OLTX for chronic hepatitis C. Two hundred and eighty-seven adult patients who underwent primary OLTX for chronic hepatitis C between December 1993 and September 1999 were studied from a prospectively maintained database. The group was stratified by MELD scores of less than 15, 15-24, and greater than 24. Patient survival, graft survival, and interval liver biopsy pathology were reviewed. Both patient and graft survival at 3, 6, and 12 months were significantly lower in the higher MELD score groups, as was patient survival at 24 months (p-values, 0.01-0.05). The difference in survival between the low, medium, and high MELD score groups increases in time. The survival without bridging fibrosis in the allograft at 1 year post-transplant was significantly lower with higher MELD scores (p = 0.037). The decrease in survival seen in hepatitis C patients with MELD scores greater than 24 raises questions of transplant suitability for these patients. Therapeutic modalities to decrease post-transplant graft injury in these patients should be explored.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12752320     DOI: 10.1034/j.1600-6143.2003.00092.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  11 in total

1.  Left-sided grafts for living-donor liver transplantation and split grafts for deceased-donor liver transplantation: their impact on long-term survival.

Authors:  Tomohide Hori; Shinji Uemoto; Lindsay B Gardner; Lena Sibulesky; Yasuhiro Ogura; Justin H Nguyen
Journal:  Clin Res Hepatol Gastroenterol       Date:  2011-09-28       Impact factor: 2.947

2.  A high MELD score, combined with the presence of hepatitis C, is associated with a poor prognosis in living donor liver transplantation.

Authors:  Toru Ikegami; Ken Shirabe; Shohei Yoshiya; Tomoharu Yoshizumi; Yo-Ichi Yamashita; Norifumi Harimoto; Takeo Toshima; Hideaki Uchiyama; Yuji Soejima; Yoshihiko Maehara
Journal:  Surg Today       Date:  2013-02-23       Impact factor: 2.549

3.  Pre-transplant MELD and sodium MELD scores are poor predictors of graft failure and mortality after liver transplantation.

Authors:  Jacek B Cywinski; Edward J Mascha; Jing You; Daniel I Sessler; Leonardo Kapural; Maged Argalious; Brian M Parker
Journal:  Hepatol Int       Date:  2011-02-17       Impact factor: 6.047

4.  Effect of nonviral factors on hepatitis C recurrence after liver transplantation.

Authors:  Andrew M Cameron; Rafik M Ghobrial; Jonathan R Hiatt; Ian C Carmody; Sherilyn A Gordon; Douglas G Farmer; Hasan Yersiz; Michael A Zimmerman; Francisco Durazo; Steve H Han; Sammy Saab; Jeffrey Gornbein; Ronald W Busuttil
Journal:  Ann Surg       Date:  2006-10       Impact factor: 12.969

5.  Pre-transplant ALBI Grade 3 Is Associated with Increased Mortality After Liver Transplantation.

Authors:  Nicole Bernardi; Marcio F Chedid; Tomaz J M Grezzana-Filho; Aljamir D Chedid; Marcelo A Pinto; Ian Leipnitz; João E Prediger; Carolina Prediger; Ariane N Backes; Thais O Hammes; Lea T Guerra; Alexandre de Araujo; Mario R Alvares-da-Silva; Cleber R P Kruel
Journal:  Dig Dis Sci       Date:  2019-01-14       Impact factor: 3.199

6.  Short-term pretransplant renal replacement therapy and renal nonrecovery after liver transplantation alone.

Authors:  Pratima Sharma; Nathan P Goodrich; Min Zhang; Mary K Guidinger; Douglas E Schaubel; Robert M Merion
Journal:  Clin J Am Soc Nephrol       Date:  2013-02-28       Impact factor: 8.237

7.  Hyponatremia and mortality among patients on the liver-transplant waiting list.

Authors:  W Ray Kim; Scott W Biggins; Walter K Kremers; Russell H Wiesner; Patrick S Kamath; Joanne T Benson; Erick Edwards; Terry M Therneau
Journal:  N Engl J Med       Date:  2008-09-04       Impact factor: 91.245

8.  Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma Patients.

Authors:  Reham Abdel-Wahab; Manal M Hassan; Bhawana George; Roberto Carmagnani Pestana; Lianchun Xiao; Sahin Lacin; Suayib Yalcin; Ahmed S Shalaby; Humaid O Al-Shamsi; Kanwal Raghav; Robert A Wolff; James C Yao; Lauren Girard; Abedul Haque; Dan G Duda; Simona Dima; Irinel Popescu; Hesham A Elghazaly; Jean-Nicolas Vauthey; Thomas A Aloia; Ching-Wei Tzeng; Yun Shin Chun; Asif Rashid; Jeffrey S Morris; Hesham M Amin; Ahmed O Kaseb
Journal:  Oncology       Date:  2020-10-07       Impact factor: 2.935

9.  Recipient Age and Mortality Risk after Liver Transplantation: A Population-Based Cohort Study.

Authors:  Hsiu-Pin Chen; Yung-Fong Tsai; Jr-Rung Lin; Fu-Chao Liu; Huang-Ping Yu
Journal:  PLoS One       Date:  2016-03-28       Impact factor: 3.240

10.  Is SAPS 3 better than APACHE II at predicting mortality in critically ill transplant patients?

Authors:  Vanessa M de Oliveira; Janete S Brauner; Edison Rodrigues Filho; Ruth G A Susin; Viviane Draghetti; Simone T Bolzan; Silvia R R Vieira
Journal:  Clinics (Sao Paulo)       Date:  2013       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.